Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection
Abstract Respiratory syncytial virus (RSV)-mediated bronchiolitis causes a significant global health burden. Despite this, for several years, the only approved agent for RSV prophylaxis was the anti-RSV monoclonal antibody Palivizumab, reserved for a small population of infants at high risk of devel...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Italian Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13052-025-01844-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861765000134656 |
|---|---|
| author | Sara Manti Eugenio Baraldi |
| author_facet | Sara Manti Eugenio Baraldi |
| author_sort | Sara Manti |
| collection | DOAJ |
| description | Abstract Respiratory syncytial virus (RSV)-mediated bronchiolitis causes a significant global health burden. Despite this, for several years, the only approved agent for RSV prophylaxis was the anti-RSV monoclonal antibody Palivizumab, reserved for a small population of infants at high risk of developing severe RSV disease. Recently, the availability and approval of nirsevimab to immunize all infants against RSV infection since their first RSV season represented a crucial paradigm shift in RSV prevention. Nirsevimab has been shown to be safe and effective (> 80%) against RSV lower respiratory tract infections (LRTIs) in all infants and children at their first season of RSV. Surveillance studies have demonstrated 90% effectiveness in reducing all-cause hospitalizations, all-cause LRTI hospitalizations, RSV-related LRTI hospitalizations, and severe RSV-related LRTIs. Moreover, the consistency and reproducibility of the beneficial outcomes coming from the prophylaxis with nirsevimab highlights its potential to deliver substantial health benefits, positioning monoclonal antibody administration as a cornerstone in the fight against RSV-related morbidity and mortality. Implementing immunization strategies for infants and children is crucial to align the international experiences and guarantee universal protection. This review provided an updated overview of the monoclonal antibody strategy for preventing RSV infection. |
| format | Article |
| id | doaj-art-e36b2ee10e6d4c4f8cdc19da77f9ec7f |
| institution | Kabale University |
| issn | 1824-7288 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Italian Journal of Pediatrics |
| spelling | doaj-art-e36b2ee10e6d4c4f8cdc19da77f9ec7f2025-02-09T12:48:08ZengBMCItalian Journal of Pediatrics1824-72882025-02-0151111110.1186/s13052-025-01844-9Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infectionSara Manti0Eugenio Baraldi1Department of Human Pathology of Adult and Childhood Gaetano Barresi, Pediatric Unit, University of MessinaDepartment of Women’s and Children’s Health, Neonatal Intensive Care Unit, University of PadovaAbstract Respiratory syncytial virus (RSV)-mediated bronchiolitis causes a significant global health burden. Despite this, for several years, the only approved agent for RSV prophylaxis was the anti-RSV monoclonal antibody Palivizumab, reserved for a small population of infants at high risk of developing severe RSV disease. Recently, the availability and approval of nirsevimab to immunize all infants against RSV infection since their first RSV season represented a crucial paradigm shift in RSV prevention. Nirsevimab has been shown to be safe and effective (> 80%) against RSV lower respiratory tract infections (LRTIs) in all infants and children at their first season of RSV. Surveillance studies have demonstrated 90% effectiveness in reducing all-cause hospitalizations, all-cause LRTI hospitalizations, RSV-related LRTI hospitalizations, and severe RSV-related LRTIs. Moreover, the consistency and reproducibility of the beneficial outcomes coming from the prophylaxis with nirsevimab highlights its potential to deliver substantial health benefits, positioning monoclonal antibody administration as a cornerstone in the fight against RSV-related morbidity and mortality. Implementing immunization strategies for infants and children is crucial to align the international experiences and guarantee universal protection. This review provided an updated overview of the monoclonal antibody strategy for preventing RSV infection.https://doi.org/10.1186/s13052-025-01844-9BronchiolitisImplementationMonoclonal antibodiesNirsevimabPreventionRecommendations |
| spellingShingle | Sara Manti Eugenio Baraldi Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection Italian Journal of Pediatrics Bronchiolitis Implementation Monoclonal antibodies Nirsevimab Prevention Recommendations |
| title | Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection |
| title_full | Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection |
| title_fullStr | Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection |
| title_full_unstemmed | Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection |
| title_short | Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection |
| title_sort | learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of rsv infection |
| topic | Bronchiolitis Implementation Monoclonal antibodies Nirsevimab Prevention Recommendations |
| url | https://doi.org/10.1186/s13052-025-01844-9 |
| work_keys_str_mv | AT saramanti learnfrominternationalrecommendationsandexperiencesofcountriesthathavesuccessfullyimplementedmonoclonalantibodyprophylaxisforpreventionofrsvinfection AT eugeniobaraldi learnfrominternationalrecommendationsandexperiencesofcountriesthathavesuccessfullyimplementedmonoclonalantibodyprophylaxisforpreventionofrsvinfection |